Počet záznamov: 1
Design and rationale of the EMPA-VISION trial: Investigating the metabolic effects of empagliflozin in patients with heart failure
Názov Design and rationale of the EMPA-VISION trial: Investigating the metabolic effects of empagliflozin in patients with heart failure Autor Hundertmark M. Spoluautori Agbaje O. Coleman R. George J. Grempler R. Holman R. Lamlum H. Lee J. Milton J. Niessen H. Rider O. Rodgers C. Valkovič Ladislav 1986 SAVMER - Ústav merania SAV SCOPUS RID ORCID Wicks E. Mahmod M. Neubauer S. Zdroj.dok. ESC Heart Failure. Vol. 8, no. 4 (2021), p. 2580-2590 Jazyk dok. eng - angličtina Druh dok. rozpis článkov z periodík (rbx) Ohlasy THIRUNAVUKARASU, S. - JEX, N. - CHOWDHARY, A. - UL HASSAN, I. - STRAW, S. - CRAVEN, T.P. - GORECKA, M. - BROADBENT, D. - SWOBODA, P. - WITTE, K.K. - CUBBON, R.M. - XUE, H. - KELLMAN, P. - GREENWOOD, J.P. - PLEIN, S. - LEVELT, E. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. In DIABETES. ISSN 0012-1797, 2021, vol. 70, no. 12, p. 2810-2822. Dostupné na: https://doi.org/10.2337/db21-0270. MORDI, I.R. - LANG, C.C. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors. In HEART FAILURE CLINICS. ISSN 1551-7136, OCT 2022, vol. 18, no. 4, p. 529-538. Dostupné na: https://doi.org/10.1016/j.hfc.2022.03.004. SELVARAJ, S. - FU, Z.X. - JONES, P. - KWEE, L.C. - WINDSOR, S.L. - ILKAYEVA, O. - NEWGARD, C.B. - MARGULIES, K.B. - HUSAIN, M. - INZUCCHI, S.E. - MCGUIRE, D.K. - PITT, B. - SCIRICA, B.M. - LANFEAR, D.E. - NASSIF, M.E. - JAVAHERI, A. - MENTZ, R.J. - KOSIBOROD, M.N. - SHAH, S.H. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. In CIRCULATION. ISSN 0009-7322, SEP 13 2022, vol. 146, no. 11, p. 808-818. Dostupné na: https://doi.org/10.1161/CIRCULATIONAHA.122.060402. SANTOS-GALLEGO, C.G. - MAYR, M. - BADIMON, J. SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism. In CIRCULATION. ISSN 0009-7322, SEP 13 2022, vol. 146, no. 11, p. 819-821. Dostupné na: https://doi.org/10.1161/CIRCULATIONAHA.122.060805. YIN, Z.W. - ZHENG, H.Z. - GUO, Z.H. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. In FRONTIERS IN CARDIOVASCULAR MEDICINE. ISSN 2297-055X, MAY 18 2022, vol. 9. Dostupné na: https://doi.org/10.3389/fcvm.2022.902923. HERNANDEZ, M. - SULLIVAN, R.D. - MCCUNE, M.E. - REED, G.L. - GLADYSHEVA, I.P. Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. In DIAGNOSTICS. APR 2022, vol. 12, no. 4. Dostupné na: https://doi.org/10.3390/diagnostics12040989. VARADHAN, A. - STEPHAN, K. - GUPTA, R. - VYAS, A.V. - RANCHAL, P. - ARONOW, W.S. - HAWWA, N. - LANIER, G.M. Growing role of SGLT2i in heart failure: evidence from clinical trials. In EXPERT REVIEW OF CLINICAL PHARMACOLOGY. ISSN 1751-2433, FEB 1 2022, vol. 15, no. 2, p. 147-159. Dostupné na: https://doi.org/10.1080/17512433.2022.2051480. SCHWITTER, J. Getting Deeper Insight by Hyperpolarization: The Multilevel Assessment of Myocardial Infarction by Adding Hyperpolarized sup13/supC-Carbon-CMR. In JACC: CARDIOVASCULAR IMAGING, 2022, vol. 15, no. 12, p. 2065-2068. ISSN 1936-878X. Dostupné na: https://doi.org/10.1016/j.jcmg.2022.09.002. MAACK, C. Mechano-energetic defects in heart failure. In HERZ. ISSN 0340-9937, 2023 MAR 2023, vol. 48, no. 2, p. 123-133. Dostupné na: https://doi.org/10.1007/s00059-022-05161-3. PALAIODIMOU, L. - KOKOTIS, P. - ZOMPOLA, C. - PAPAGIANNOPOULOU, G. - BAKOLA, E. - PAPADOPOULOU, M. - ZOUVELOU, V. - PETRAS, D. - VLACHOPOULOS, C. - TSIVGOULIS, G. Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review. In CURRENT NEUROPHARMACOLOGY. ISSN 1570-159X, 2023, vol. 21, no. 3, p. 440-456. Dostupné na: https://doi.org/10.2174/1570159X20666220601124117. GITTO, M. - VILLASCHI, A. - FEDERICI, M. - CONDORELLI, G. - STEFANINI, G.G. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. In CURRENT PHARMACEUTICAL DESIGN. ISSN 1381-6128, 2023, vol. 29, no. 7, p. 481-493. Dostupné na: https://doi.org/10.2174/1381612829666230217143324. AGUIAR-NEVES, I. - SANTOS-FERREIRA, D. - FONTES-CARVALHO, R. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier. In REVIEWS IN CARDIOVASCULAR MEDICINE. ISSN 1530-6550, JAN 2023, vol. 24, no. 1. Dostupné na: https://doi.org/10.31083/j.rcm2401001. XIE, Y.F. - WEI, Y.J. - LI, D. - PU, J. - DING, H. - ZHANG, X.W. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. In JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. ISSN 0160-2446, JAN 2023, vol. 81, no. 1, p. 4-14. Dostupné na: https://doi.org/10.1097/FJC.0000000000001380. PISTELLI, L. - PARISI, F. - CORREALE, M. - COCUZZA, F. - CAMPANELLA, F. - DE FERRARI, T. - CREA, P. - DE SARRO, R. - LA COGNATA, O. - CERATTI, S. - RECUPERO, T. - RUOCCO, G. - PALAZZUOLI, A. - IMBALZANO, E. - DATTILO, G. Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy-A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. In JOURNAL OF CLINICAL MEDICINE. JAN 2023, vol. 12, no. 1. Dostupné na: https://doi.org/10.3390/jcm12010379. SONG, C. - HUANG, Z. - CHEN, W. - WANG, F. - CAI, L. - ZHAO, F. - ZHAO, Y. Empagliflozin alleviates cardiac microvascular ischemia/reperfusion injury by maintaining myocardial mitochondrial homeostasis. In NAN FANG YI KE DA XUE XUE BAO / JOURNAL OF SOUTHERN MEDICAL UNIVERSITY, 2023, vol. 43, no. 7, p. 1136-1144. ISSN 1673-4254. Dostupné na: https://doi.org/10.12122/j.issn.1673-4254.2023.07.10. CORREALE, M. - LAMACCHIA, O. - CICCARELLI, M. - DATTILO, G. - TRICARICO, L. - BRUNETTI, N.D. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. In HEART FAILURE REVIEWS, 2023, vol. 28, no. 3, p. 733-744. ISSN 1382-4147. Dostupné na: https://doi.org/10.1007/s10741-021-10157-y. MUNTEANU, M.A. - SWARNKAR, S. - POPESCU, R.-I. - LUNGU, A. - CIOBOTARU, L. - NICOLAE, C. - TUFANOIU, E. – NANEA, I.T. SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics? In MAEDICA (BUCUR). ISSN 1841-9038, 2023, vol. 18, no. 1, p. 102–110. Dostupné na: https://doi.org/10.26574%2Fmaedica.2023.18.1.102. CHO, D.-H. SGLT2 Inhibitors: Emerging Drugs in Heart Failure. In KOREAN JOURNAL OF MEDICINE. ISSN 1738-9364, 2023, vol. 98, no. 2, p. 59-63. Dostupné na: https://doi.org/10.3904/kjm.2023.98.2.59. DOS SANTOS, J. - DAWSON, S. - CONEFREY, C. - ISAACS, T. - KHANUM, M. - FAISAL, S. - PARAMASIVAN, S. Most UK cardiovascular disease trial protocols feature criteria that exclude ethnic minority participants: a systematic review. In JOURNAL OF CLINICAL EPIDEMIOLOGY. ISSN 0895-4356, MAR 2024, vol. 167. Dostupné na: https://doi.org/10.1016/j.jclinepi.2024.111259. Kategória ADCA - Vedecké práce v zahraničných karentovaných časopisoch impaktovaných Kategória (od 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Typ výstupu článok Rok vykazovania 2021 Registrované v WOS Registrované v SCOPUS Registrované v CCC DOI 10.1002/ehf2.13406 
článok
Názov súboru Prístup Veľkosť Stiahnuté Typ Licence Design and rationale of the EMPA-VISION trial.pdf Prístupný 444.2 KB 2 Vydavateľská verzia rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2021 2020 4.411 Q2 0.787 Q2
Počet záznamov: 1